«

Through this AI Accelerator Grant, we can harness AI to understand ovarian cancer and its impact on women faster than ever.

Tania Vrionis, CEO, Ovarian Cancer Canada

Artificial Intelligence (AI) and Ovarian Cancer

The Consortium’s AI Accelerator Grants are designed to support innovative, data-intensive research projects that leverage cutting-edge computational approaches to address some of the most pressing challenges in ovarian cancer, including but not limited to prevention, initiation, and early detection; the tumor ecosystem; and treatment resistance.  The initiative builds on the Consortium’s mission to unite global expertise and resources to drive faster, more meaningful breakthroughs and advance research that improves survival and outcomes for patients worldwide.

AI is already revolutionizing cancer diagnoses—from breast to brain, skin to thyroid—with stunning advances. But ovarian cancer has yet to realize the full power of this transformation – funding has lagged behind other diseases despite the high mortality rate and rising number of diagnoses. The Consortium is committed to changing this, launching their first $1 million initiative last year. Twenty-one international teams, each comprised of researchers from Australia, Canada, the United Kingdom and the United States competed, with the first grant announced earlier this year.

Through this AI Accelerator Grant, we can harness AI to understand ovarian cancer and its impact on women faster than ever,” said Tania Vrionis, CEO of Ovarian Cancer Canada, the only national health charity in Canada dedicated to transforming the lives of those diagnosed with ovarian cancer. “Our global philanthropic partnership, support from Amazon Web Services, and international research collaboration are key to accelerating change. After decades without real progress, women facing ovarian cancer deserve breakthroughs as quickly as we can make them.”

About the AI Accelerator Grant

As part of the grant, selected researchers will receive in-kind cloud compute credits from Amazon Web Services (AWS) to use within Ovarian Cancer Research Alliance’s AI-enabled, international, collaborative research platform. By anchoring the work within this shared ecosystem, the Consortium ensures that research funded by the AI Accelerator Grant is conducted in a scalable setting that enables real-time data analysis, cross-institutional collaboration, and the integration of diverse datasets. The Consortium is helping to transform how research is conducted, shifting from isolated efforts to a connected, global model of discovery.

The Global Ovarian Cancer Research Consortium includes Ovarian Cancer Research Alliance (United States), Ovarian Cancer Action (United Kingdom), Ovarian Cancer Canada (Canada), and Ovarian Cancer Research Foundation (Australia). Recognizing the need for innovation and worldwide collaboration, the Consortium was created to accelerate progress by uniting stakeholders in collective action to advance collaboration, innovation, and investment in transformative research, promote data sharing, and address unmet needs and access gaps.

Letters of Intent for the AI Accelerator Grant open today, May 8.